Effect of Metformin as add-on Therapy on Glycemic Control and Other Outcomes in Type 1 Diabetes
NCT ID: NCT03590262
Last Updated: 2018-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2018-01-01
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Metformin on Gut Microbiota Changes and Glycemic Control of Newly Diagnosed Type 2 Diabetes
NCT04426422
the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin
NCT02438397
The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM
NCT02765347
Metformin Plus Insulin on Non-obese Autoimmune Diabetes
NCT03513874
Effect of Metformin and Probiotics on Gut Microbiome in Healthy Subjects
NCT03756623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Outcomes Primary outcomes were glycemic control related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The gut microbiota profile will be analyzed before and after intervention .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
metformin
patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
Metformin
take the metformin 500mg twice or three times a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin
take the metformin 500mg twice or three times a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fengyi Yuan
Role: PRINCIPAL_INVESTIGATOR
associate chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Ping Xu
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
723
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.